Octapharma USA Announces FDA Approval Of NUWIQ New Product Strengths, Expanding Hemophilia A Patient Treatment Options

Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved new product strengths for NUWIQ, offering added convenience by potentially reducing the number of vials needed for Hemophilia A patients. The agency approved new single dose NUWIQ vial strengths of 2500, 3000 and 4000 International Units (IU), which will be available for ordering in the U.S. starting September 2017. These new vial strengths will be provided in addition to the already available strengths of 250, 500, 1000 or 2000 IU. NUWIQ® is the only recombinant Factor VIII (FVIII) providing patients a wide array of vials with the lowest diluent volume of 2.5ml.